THE TREATMENT OF MULTIPLE MYELOMA PATIENTS NOT ELIGIBLE FOR ASCT
<p class="MsoNormal" style="margin: 0cm 0cm 0pt; line-height: 150%; mso-layout-grid-align: none;"><span style="font-size: small;"><span style="font-family: ";Arial";,";sans-serif";; mso-ansi-language: EN-GB; ms...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
PAGEPress Publications
2010-05-01
|
| Series: | Mediterranean Journal of Hematology and Infectious Diseases |
| Subjects: | |
| Online Access: | http://www.mjhid.org/article/view/5779 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850058988614320128 |
|---|---|
| author | Anuj Mahindra Jacob Laubach Paul Richardson Constantine Mitsiades Robert Schlossman Irene Ghobrial Teru Hideshima Noopur Raje Nikhil Munshi Kenneth Anderson |
| author_facet | Anuj Mahindra Jacob Laubach Paul Richardson Constantine Mitsiades Robert Schlossman Irene Ghobrial Teru Hideshima Noopur Raje Nikhil Munshi Kenneth Anderson |
| author_sort | Anuj Mahindra |
| collection | DOAJ |
| description | <p class="MsoNormal" style="margin: 0cm 0cm 0pt; line-height: 150%; mso-layout-grid-align: none;"><span style="font-size: small;"><span style="font-family: ";Arial";,";sans-serif";; mso-ansi-language: EN-GB; mso-fareast-language: EN-GB;" lang="EN-GB">Advances in therapies for younger patients with multiple myeloma have resulted in significant</span><strong style="mso-bidi-font-weight: normal;"><span style="font-family: ";Arial";,";sans-serif";; mso-ansi-language: EN-GB;" lang="EN-GB"> </span></strong><span style="color: black; font-family: ";Arial";,";sans-serif";; mso-ansi-language: EN-GB; mso-fareast-language: EN-GB;" lang="EN-GB">improvements in outcome over recent years,</span><span style="font-family: ";Arial";,";sans-serif";; mso-ansi-language: EN-GB; mso-fareast-language: EN-GB;" lang="EN-GB"> on the contrary the<span style="color: black;"> progress in treatments for elderly patients has remained more modest. Traditionally, patients <span style="mso-spacerun: yes;"> </span><span style="mso-spacerun: yes;"> </span>who are not eligible for transplantation, like the older patients, <span style="mso-spacerun: yes;"> </span>have been treated with the combination of melphalan plus prednisone (MP), which leads to responses in approximately 50% of patients; however, patients rarely achieve a complete response (CR) and long-term outcomes are disappointing, with a relapse-free survival of approximately 18 months and an overall survival (OS) of approximately 3 years.</span></span></span></p><p class="MsoNormal" style="margin: 0cm 0cm 0pt; line-height: 150%; mso-layout-grid-align: none;"><span style="color: black; font-family: ";Arial";,";sans-serif";; mso-ansi-language: EN-GB; mso-fareast-language: EN-GB;" lang="EN-GB"><span style="font-size: small;">With the arrival of novel agents, including the first–in-class proteasome inhibitor, bortezomib, and the immunomodulatory agents, thalidomide and lenalidomide, a shift in the management of older patients and/or those not eligible for transplantation has taken place. Increasingly, novel agents are now being incorporated into therapy, based on the positive findings from clinical trials in this setting, and outcomes have improved accordingly.</span></span></p> |
| format | Article |
| id | doaj-art-73c5faa66eac4af586348da8c403d09e |
| institution | DOAJ |
| issn | 2035-3006 |
| language | English |
| publishDate | 2010-05-01 |
| publisher | PAGEPress Publications |
| record_format | Article |
| series | Mediterranean Journal of Hematology and Infectious Diseases |
| spelling | doaj-art-73c5faa66eac4af586348da8c403d09e2025-08-20T02:51:00ZengPAGEPress PublicationsMediterranean Journal of Hematology and Infectious Diseases2035-30062010-05-0122e2010009e2010009THE TREATMENT OF MULTIPLE MYELOMA PATIENTS NOT ELIGIBLE FOR ASCTAnuj MahindraJacob LaubachPaul RichardsonConstantine MitsiadesRobert SchlossmanIrene GhobrialTeru HideshimaNoopur RajeNikhil MunshiKenneth Anderson<p class="MsoNormal" style="margin: 0cm 0cm 0pt; line-height: 150%; mso-layout-grid-align: none;"><span style="font-size: small;"><span style="font-family: ";Arial";,";sans-serif";; mso-ansi-language: EN-GB; mso-fareast-language: EN-GB;" lang="EN-GB">Advances in therapies for younger patients with multiple myeloma have resulted in significant</span><strong style="mso-bidi-font-weight: normal;"><span style="font-family: ";Arial";,";sans-serif";; mso-ansi-language: EN-GB;" lang="EN-GB"> </span></strong><span style="color: black; font-family: ";Arial";,";sans-serif";; mso-ansi-language: EN-GB; mso-fareast-language: EN-GB;" lang="EN-GB">improvements in outcome over recent years,</span><span style="font-family: ";Arial";,";sans-serif";; mso-ansi-language: EN-GB; mso-fareast-language: EN-GB;" lang="EN-GB"> on the contrary the<span style="color: black;"> progress in treatments for elderly patients has remained more modest. Traditionally, patients <span style="mso-spacerun: yes;"> </span><span style="mso-spacerun: yes;"> </span>who are not eligible for transplantation, like the older patients, <span style="mso-spacerun: yes;"> </span>have been treated with the combination of melphalan plus prednisone (MP), which leads to responses in approximately 50% of patients; however, patients rarely achieve a complete response (CR) and long-term outcomes are disappointing, with a relapse-free survival of approximately 18 months and an overall survival (OS) of approximately 3 years.</span></span></span></p><p class="MsoNormal" style="margin: 0cm 0cm 0pt; line-height: 150%; mso-layout-grid-align: none;"><span style="color: black; font-family: ";Arial";,";sans-serif";; mso-ansi-language: EN-GB; mso-fareast-language: EN-GB;" lang="EN-GB"><span style="font-size: small;">With the arrival of novel agents, including the first–in-class proteasome inhibitor, bortezomib, and the immunomodulatory agents, thalidomide and lenalidomide, a shift in the management of older patients and/or those not eligible for transplantation has taken place. Increasingly, novel agents are now being incorporated into therapy, based on the positive findings from clinical trials in this setting, and outcomes have improved accordingly.</span></span></p>http://www.mjhid.org/article/view/5779Myeloma,New Drugs, Older People, Bortezomid, Thalidomide, Revlimid |
| spellingShingle | Anuj Mahindra Jacob Laubach Paul Richardson Constantine Mitsiades Robert Schlossman Irene Ghobrial Teru Hideshima Noopur Raje Nikhil Munshi Kenneth Anderson THE TREATMENT OF MULTIPLE MYELOMA PATIENTS NOT ELIGIBLE FOR ASCT Mediterranean Journal of Hematology and Infectious Diseases Myeloma,New Drugs, Older People, Bortezomid, Thalidomide, Revlimid |
| title | THE TREATMENT OF MULTIPLE MYELOMA PATIENTS NOT ELIGIBLE FOR ASCT |
| title_full | THE TREATMENT OF MULTIPLE MYELOMA PATIENTS NOT ELIGIBLE FOR ASCT |
| title_fullStr | THE TREATMENT OF MULTIPLE MYELOMA PATIENTS NOT ELIGIBLE FOR ASCT |
| title_full_unstemmed | THE TREATMENT OF MULTIPLE MYELOMA PATIENTS NOT ELIGIBLE FOR ASCT |
| title_short | THE TREATMENT OF MULTIPLE MYELOMA PATIENTS NOT ELIGIBLE FOR ASCT |
| title_sort | treatment of multiple myeloma patients not eligible for asct |
| topic | Myeloma,New Drugs, Older People, Bortezomid, Thalidomide, Revlimid |
| url | http://www.mjhid.org/article/view/5779 |
| work_keys_str_mv | AT anujmahindra thetreatmentofmultiplemyelomapatientsnoteligibleforasct AT jacoblaubach thetreatmentofmultiplemyelomapatientsnoteligibleforasct AT paulrichardson thetreatmentofmultiplemyelomapatientsnoteligibleforasct AT constantinemitsiades thetreatmentofmultiplemyelomapatientsnoteligibleforasct AT robertschlossman thetreatmentofmultiplemyelomapatientsnoteligibleforasct AT ireneghobrial thetreatmentofmultiplemyelomapatientsnoteligibleforasct AT teruhideshima thetreatmentofmultiplemyelomapatientsnoteligibleforasct AT noopurraje thetreatmentofmultiplemyelomapatientsnoteligibleforasct AT nikhilmunshi thetreatmentofmultiplemyelomapatientsnoteligibleforasct AT kennethanderson thetreatmentofmultiplemyelomapatientsnoteligibleforasct AT anujmahindra treatmentofmultiplemyelomapatientsnoteligibleforasct AT jacoblaubach treatmentofmultiplemyelomapatientsnoteligibleforasct AT paulrichardson treatmentofmultiplemyelomapatientsnoteligibleforasct AT constantinemitsiades treatmentofmultiplemyelomapatientsnoteligibleforasct AT robertschlossman treatmentofmultiplemyelomapatientsnoteligibleforasct AT ireneghobrial treatmentofmultiplemyelomapatientsnoteligibleforasct AT teruhideshima treatmentofmultiplemyelomapatientsnoteligibleforasct AT noopurraje treatmentofmultiplemyelomapatientsnoteligibleforasct AT nikhilmunshi treatmentofmultiplemyelomapatientsnoteligibleforasct AT kennethanderson treatmentofmultiplemyelomapatientsnoteligibleforasct |